Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
NCT00322257 · Novo Nordisk A/S · PHASE3 · terminated · last registry update 2018-09-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “See termination reason in detailed description” | – | Registry record, Novo Nordisk A/S |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-08-07Results posted on the registry: Indiana University, liraglutide + insulin detemir (NCT01232946)
- 2019-07-29Results posted on the registry: Novo Nordisk A/S, insulin degludec/liraglutide + insulin degludec (NCT02607306)
- 2019-07-23Also stopped (withdrawn): Institut de Recherches Cliniques de Montreal, Insulin + Glucagon (NCT02846857)
- 2019-07-17Phase 3 first posted: Geropharm, Humalog Mix25 + Insulin Lispro Biphasic 25 (NCT04023344)
- 2019-06-03Results posted on the registry: University of Oxford, Linsitinib (NCT02546544)
- 2019-05-16Phase 3 first posted: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03952130)
- 2019-05-16Phase 3 first posted: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03952143)
- 2019-05-01Results posted on the registry: Sanofi, Insulin glargine, 300 U/ml + Insulin glargine, 100 U/ml (NCT02451137)
- 2019-04-04Results posted on the registry: Novo Nordisk A/S, Faster-acting insulin aspart + insulin aspart (NCT02670915)
- 2019-03-20Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Insulin Degludec (NCT03882970)
- 2019-03-20Results posted on the registry: University of Michigan, Insulin treatment for hyperglycemia (NCT01683331)
- 2019-03-15Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Insulin Glargine (NCT01894568)
- 2019-03-11Results posted on the registry: Novo Nordisk A/S, Insulin degludec/liraglutide + Insulin degludec (NCT02911948)
- 2019-03-11Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Insulin Glargine (NCT01771250)
- 2019-03-06Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Human Insulin (NCT02109029)
- 2019-03-05Phase 3 first posted: Population Health Research Institute, IDegLira + insulin degludec (NCT03862716)
- 2019-03-01Results posted on the registry: Eli Lilly and Company, LY2605541 + Insulin Glargine (NCT01925989)
- 2019-03-01Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Insulin Lispro (NCT02152384)
- 2019-01-16Also stopped (withdrawn): University of Texas Southwestern Medical Center, Levemir (Detemir) and Novolog (Aspart) Insulin (NCT00906529)
- 2019-01-15Results posted on the registry: Cairo University, regular insulin + 70/30 insulin (NCT01855243)
- 2018-12-07Results posted on the registry: Novo Nordisk A/S, insulin degludec/insulin aspart + biphasic insulin aspart (NCT02762578)
- 2018-11-28Results posted on the registry: The University of Texas Health Science Center, Houston, Metformin + Insulin (NPH and Regular) (NCT00678080)
- 2018-11-14Phase 3 first posted: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03740919)
- 2018-11-09Phase 3 first posted: Emory University, IDegLira + Insulin Degludec (U-100) (NCT03737240)
- 2018-11-01Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Insulin Glargine (NCT02197520)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision